Table 1: Aggregated summary of the characteristics of the studied patient cohorts. (A) Demographics of the radical prostatectomy (RP) patient cohort including the 536 patients eligible for statistical data analysis. For patient age, preoperative PSA, percentage of tumour in biopsy, prostate volume, and PSA density the min and max values in the cohort are shown; median and IQR (interquartile range) are shown in parentheses. Pre- and postsurgical pathology is given (Note. extracapsular extension was derived from pathology stage information). The outcome category illustrates the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence to metastases (CR) postsurgical primary treatment. The treatment category lists the cumulative 5- and 10-year start to SRT (salvage radiation therapy) or SADT (salvage androgen deprivation therapy) after surgery. Mortality is shown as prostate cancer specific survival (PCSS) as well as overall survival (OS) (N/A=not available). (B) Demographics of the diagnostic biopsy (DB) patient cohort. In total diagnostic needle biopsy tissues of 151 were eligible for statistical data analysis. The demographics and clinical data of this cohort are presented equivalent to the RP cohort (N/A=not available).

Parameter(A) RP cohort (n=536)(B) DB cohort (n=151)

Demographic & Clinical
Range (median; IQR)
Age range (at RP)41.3-74.5 (62.5; 7.5)47.4-77.4 (64.9; 8.5)
Preoperative PSA range0.18-120 (7.1; 6.2)2.0-49.1 (8.1; 5.7)
Percent tumour in biopsy range0.2-80.0 (10.6; 20.2)N/A
Prostate Volume range9-244 (41.0; 21.0)13.6-148.0 (38.5; 19.2)
PSA density range0.01-4.0 (0.17; 0.16)0.03-1.6 (0.2; 0.17)

CAPRA Risk Category
Number of patients (percentage)
Low Risk (CARPA 0-2)199 (37.1%)38 (25.2%)
Intermediate Risk (CAPRA 3-5)273 (50.9%)82(54.3%)
High Risk (CAPRA>5)44 (8.2%)31 (20.5%)
N/A20 (3.7%)-

Pre-Surgery Pathology
Number of patients (percentage)
Biopsy Gleason 3+3 (GG1)282 (52.6%)77 (51.0%)
Biopsy Gleason 3+4 (GG2)172 (32.1%)38 (25.2%)
Biopsy Gleason 4+3 (GG3)46 (8.6%)20 (13.2%)
Biopsy Gleason >=4+4 (>=GG4)36 (6.7%)16 (10.6%)
cT1348 (64.9%)97 (64.2%)
cT2175 (32.6%)
cT313 (2.3%)54 (35.8%)
N/A1 (0.2%)-

Post-Surgery Pathology
Number of patients (percentage)
Pathology Gleason 3+3 (GG1)176 (32.8%)46 (30.5%)
Pathology Gleason 3+4 (GG2)268 (50.0%)52 (34.4%)
Pathology Gleason 4+3 (GG3)69 (12.9%)31 (20.5%)
Pathology Gleason >=4+4 (>=GG4)23 (4.3%)22 (14.6%)
pT2312 (58.2%)88 (58.3%)
pT3224 (41.8%)63 (41.7%)
pT40 (0%)0 (0%)
Positive Surgical Margins197 (36.8%)33 (21.9%)
Extra-Capsular Extension (=T3a)139 (25.9%)37/151 (24.5%)
Seminal Vesicle Invasion87 (16.2%)N/A
Lymph Node Invasion17 (3.2%)10 (6.6%)

Follow-up
(months)
Mean105.173.7
Median120.273.6

Outcome– 
Number events/total patient number (percentage)
BCR within 5 years169/480 (35.2%)45/151 (29.8%)
BCR within 10 years210/402 (52.2%)-
CR within 5 years46/472 (9.7%)4/151 (2.6%)
CR within 10 years61/337 (18.1%)-

Salvage Treatment – 
Number events/total patient number (percentage)
SRT within 5 years130/475 (27.4%)12/151 (7.9%)
SRT within 10 years164/381 (43.0%)-
SADT within 5 years75/467 (16.1%)16/151 (10.6%)
SADT within 10 years110/350 (31.4%)-

Survival– 
Number events/total patient number (percentage)
PCSS within 5 years13/453 (2.9%)1/151 (0.7%)
PCSS within 10 years25/304 (8.2%)-
OS within 5 years25/465 (5.4%)1/151 (0.7%)
OS within 10 years51/331 (15.4%)-